Explore the vast range of titles available.

The use of gene technology to modify the genome of wine yeasts belonging to the species Saccharomyces cerevisiae began in the early 1990s. From a purely scientific point of view, many yeast constructs [genetically modified organisms (GMO)] have been made so far, covering more or less all stages of the wine making process in which microorganisms or commercial enzymes play a key role. The range of theoretical applications is summarised in this report. So far, only two wine-producing countries worldwide allow the use of engineered wine yeasts; the changing situation in Germany regarding consumers’ attitudes towards gene technology, and foodstuffs thus produced, will be outlined here. Experiments at the Geisenheim Research Center have highlighted the essential stages of the wine making process where yeasts are involved by using engineered wine yeasts in comparison with non-engineered yeast strains. Greenhouse simulations revealed the persistence of genetically modified (gm) yeasts when these were used as fertilizers, as vintners do with yeast lees after the fermentation process. Furthermore, the persistence of engineered yeast was also monitored in fermentations, after bottling, and after biological treatment of winery waste water. It turned out that engineered wine yeast strains behave like non-engineered wine yeasts. They also persist in the winery interior and installations as well as becoming part of the yeast flora on grape vines in a vineyard with annual fluctuations in the composition of the yeast populations.

Approved pharmacological treatments for alcohol use disorder are limited in their effectiveness, and new drugs that can easily be translated into the clinic are warranted. One of those candidates is oxytocin because of its interaction with several alcohol-induced effects. Alcohol-dependent rats as well as post-mortem brains of human alcoholics and controls were analyzed for the expression of the oxytocin system by qRT-PCR, in situ hybridization, receptor autoradiography ([125 I]OVTA binding), and immunohistochemistry. Alcohol self-administration and cue-induced reinstatement behavior was measured after intracerebroventricular injection of 10 nM oxytocin in dependent rats. Here we show a pronounced upregulation of oxytocin receptors in brain tissues of alcohol-dependent rats and deceased alcoholics, primarily in frontal and striatal areas. This upregulation stems most likely from reduced oxytocin expression in hypothalamic nuclei. Pharmacological validation showed that oxytocin reduced cue-induced reinstatement response in dependent rats--an effect that was not observed in non-dependent rats. Finally, a clinical pilot study (German clinical trial number DRKS00009253) using functional magnetic resonance imaging in heavy social male drinkers showed that intranasal oxytocin (24 IU) decreased neural cue-reactivity in brain networks similar to those detected in dependent rats and humans with increased oxytocin receptor expression. These studies suggest that oxytocin might be used as an anticraving medication and thus may positively affect treatment outcomes in alcoholics.